Teva Inks $40.5 Billion Deal to Acquire Allergan’s Generics Unit
7/28/2015 The global pharmaceutical landscape was significantly altered on Monday as Israeli drugmaker Teva announced that it will purchase the generic drug business of Dublin-based Allergan. The move will put a stranglehold on Teva’s top sales position in the generic drug market, acquiring its third-largest competitor. Teva will purchase the generics unit for $40.5 billion,